

1/9/04

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)

Atty. Docket No.

1579-880

Applicant

Divisional of Serial No.

~~09/775,805~~ 10/753339

HAYNES et al

Filing Date

January 9, 2004

Group

1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

✓	Sheppard et al, "The characterization of non-progressors: long-term HIV-1 infection will stable CD4+ T-cell levels", AIDS 7:1159-1166 (1993)
✓	Phair, John P., Keynote Address: "Variations in the Natural History of HIV Infection", AIDS Research and Human Retroviruses 10(8):883-885 (1994)
✓	Pantaleo et al, "Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection", N. Engl. J. Med. 332(4):209-216 (1995)
✓	Cao et al, "Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection", N. Engl. J. Med. 332(4):201-208 (1995)
✓	Pantaleo et al, "Major expansion of CD8+ T cells with a predominant Vβ usage during the primary Immune response to HIV", Nature 397:463-467 (1994)
✓	Mellors et al, "Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion", Ann. Intern. Med. 122:573-579 (1995)
✓	Jurriaans et al, "The Natural History of HIV-1 Infection: Virus Load and Virus Phenotype Independent Determinants of Clinical Course?", Virology 204:223-233 (1994)
✓	Borrow et al, "Virus-Specific CD8+ Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection", Journal of Virology 68(9):6103-6110 (1994)
✓	Haynes et al, "Toward an Understanding of the Correlates of Protective Immunity to HIV Infection", Science 271:324-328 (1996)
✓	Haynes, Barton F., "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development", Science 260:1279-1286 (1993)
✓	Nowak et al, "Antigenic oscillations and shifting Immunodominance in HIV-1 Infections", Nature 375:606-611 (1995)
✓	Walker et al, "CD8+ Lymphocytes Can Control HIV Infection in Vitro by Suppressing Virus Replication", Science 234:1563-1566 (1986)
✓	Baler et al, "HIV suppression by interleukin-16", Nature 378:563 (1995)
✓	Cocchi et al, "Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells", Science 270:1811-1815 (1995)
✓	Feng et al, "HIV-1 Entry Cofactor" Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor", Science 272:872-877 (1996)
✓	Wei et al, "Viral dynamics in human immunodeficiency virus type 1 infection", 373:117-122 (1995)
✓	Palker et al, "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen Comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes", The Journal of Immunology 142:3612-3619 (1989)
✓	Berzofsky, Jay A., "Development of artificial vaccines against HIV using defined epitopes", The FASEB Journal 5:2412-2418 (1991)
✓	Haynes et al, "HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen", AIDS Research and Human Retroviruses 11(2):211-221 (1995)

*Examiner		Date Considered	1/11/05
-----------	--	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

1579-880

APPLICANT

HAYNES et al

FILING DATE

DIVISIONAL OF SERIAL NO.

09/775,805

(Use several sheets if necessary)

GROUP

January 9, 2004

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

						ABSTRACT	
DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
<i>ps</i>	WO 01/56355	8/2001	PCT	—	—		
	/						

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

[illegible]

• Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)

Atty. Dock t No.

Divisional of Serial No.

1579-880

09/775,805

Applicant

HAYNES t al

Filing Date

Group

January 9, 2004

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	/					

FOREIGN PATENT DOCUMENTS

DOCUMENT							TRANSLATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
P	✓	WO 03/039470	5/2003	PCT	—	—		
	✓	WO 01/56355	8/2001	PCT	—	—		
		/						

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

✓	Lee et al, "Circulating HIV-1-Infected Cell Burden From Seroconversion to AIDS: Importance of Postseroconversion Viral Load on Disease Course", Journal of Acquired Immune Deficiency Syndromes 7:381-388 (1994)
✓	Rowland-Jones et al, "HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women", Nature Medicine 1(1):59-64 (1995)
✓	Wain-Hobson et al, "Simon in the Evolutionary biology of viruses, Stephen S. Morse (ed), Raven Press, NY, pgs 185-209 (1994) - Abstract
✓	Ho et al, "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection", Nature 373:123-126 (1995)
✓	Robertson et al, "Recombination in AIDS Viruses", Journal of Molecular Evolution 40:249-259 (1995)
✓	Haynes et al, "Use of Synthetic Peptides in Primates to Induce High-Titered Neutralizing Antibodies and MHC Class I-Restricted Cytotoxic T Cells Against Acquired Immunodeficiency Syndrome Retroviruses: An HLA-Based Vaccine Strategy", Transactions of the Association of American Physicians 106:33-41 (1993)
✓	Ward et al, "Analysis of HLA Frequencies in Population Cohorts for Design of HLA-Based HIV Vaccines", HIV Molecular Database, pages IV-10 - IV-16 (1995)
✓	Mayr et al, "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parental Vaccination and Behavior in Organisms with a Debilitated Defence Mechanism", Zbl. Bakt. Hyg. I. Abt. Orig. B 167:375-390 (1978) <i>Only the English abstract considered</i>
✓	Bartlett et al, "Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen", AIDS 12:1291-1300 (1998)
✓	Haynes et al, "HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3-Peptides as a Polyvalent Immunogen", AIDS Research and Human Retroviruses 11(2):211-221 (1995)

*Examiner

Date Considered

1/11/05

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)

Atty. Docket No.

Divisional of Serial No.

1579-880

09/775,805

Applicant

HAYNES t al

Filing Date

Group

January 9, 2004

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/	5,030,449	7/1991	Berzofsky et al			
/	5,853,978	12/1998	Berman et al			
/	5,864,027	1/1999	Berman			
/	5,932,218	8/1999	Berzofsky et al			
/	5,939,074	8/1999	Berzofsky et al			
/	6,042,836	3/2000	Berman et al			
/	6,290,963	9/2001	Fischinger et al			
/	6,294,322	9/2001	Berzofsky et al			
/	6,458,527	10/2002	Luciw et al			
/	5,081,226	1/1992	Berzofsky et al			
/	5,336,758	8/1994	Berzofsky et al			
/	5,622,703	4/1997	Berzofsky et al			
/	5,695,762	12/1997	Berzofsky et al			
/	5,711,947	1/1998	Berzofsky et al			
/	5,820,865	10/1998	Berzofsky et al			
/	5,882,853	3/1999	Berzofsky et al			
/	5,976,541	11/1999	Berzofsky et al			
/	5,980,899	11/1999	Berzofsky et al			
/	5,997,869	12/1999	Goletz et al			
/	6,214,347	4/2001	Berzofsky et al			
/	6,592,872	7/2003	Klimpel et al			

FOREIGN PATENT DOCUMENTS

						ENGLISH ABSTRACT		
DOCUMENT		DATE	COUNTRY		CLASS	SUBCLASS	YES	NO
	✓	WO 93/04697	3/1993	WIPO				
	✓	WO 94/26785	11/1994	WIPO				
	✓	WO 94/28929	12/1994	WIPO				
	✓	WO 94/29339	12/1994	WIPO				
	✓	WO 98/01564	1/1998	WIPO				
	✓	WO 02/08716	1/2002	WIPO			X	
	✓	WO 2002/20554	3/2002	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/	Ahlers, et al., "Construction of an HIV-1 Peptide Vaccine Containing a Multideterminant Helper Peptide Linked to a V3 Loop Peptide 18 Inducing Strong Neutralizing Antibody Responses in Mice of Multiple MHC Haplotypes After Two Immunizations", The Journal of Immunology, Vol. 150, No. 12, pp. 5647-5665 (1993)
/	Ahlers, et al., "Candidate HIV Type 1 Multideterminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All Using the Same Adjuvant Immunization", AIDS Research and Human Retroviruses, Vol. 12, Number 4, pp. 259-272 (1996)
/	Berzofsky, et al., "Antigenic Peptides Recognized by T lymphocytes from AIDS Viral Envelope-Immune Humans", Nature, Vol. 334, pp. 706-708 (1988)

*Examiner


Date Considered

1/11/05

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.

1579-880

SERIAL NO.

10/753,339

APPLICANT

HAYNES et al

FILING DATE

January 9, 2004

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>js</i>	✓ 5,976,551	11/1999	Mottez et al	—	—	
<i>js</i>	✓ 6,656,471	12/2003	Sasry et al	—	—	

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>js</i>	✓	WO 91/04051	4/1991	WIPO				
	✓	WO 00/52040	9/2000	WIPO				
	✓	WO 02/20555	3/2002	WIPO				
	✓	WO 02/069691	9/2002	WIPO				
	✓	WO 01/43693	6/2001	WIPO				
	✓	WO 01/54719	8/2001	WIPO				
	✓	WO 96/41189	12/1996	WIPO				
	✓	EP 0 693 938 B1	1/1996	Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

<i>js</i>	✓	Novitsky et al, "Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design", Journal of Virology 75(19):9210-9228 (2001)
	✓	Wilson et al, "Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes", Journal of Virology 75(9):4195-4207 (2001)
	✓	Hinkula et al, "Epitope Mapping of the HIV-1 gag Region with Monoclonal Antibodies", Molecular Immunology 27(5):395-403 (1990)
	✓	Michel et al, "HIV-1 Env, Nef, and Gag-specific T-Cell Immunity in Mice: Conserved Epitopes in NefP27 and Gag P25 Proteins", AIDS Research and Human Retroviruses 8(4):469-478 (1992)
	✓	Mills et al, "HIV p24-specific Helper T Cell Clones from Immunized Primates Recognize Highly Conserved Regions of HIV-1", J. Immunol. 144:1677-1683 (1990)
	✓	Nixon et al, "HIV-1 gag-specific Cytotoxic T Lymphocytes Defined with Recombinant Vaccinia Virus and Synthetic Peptides", Nature 336:484-487 (1988)
	✓	Baier et al, "HIV Suppression by Interleukin-16", Nature 378:563 (1995)
	✓	Goulder et al, "Novel, Cross-Restricted, Conserved, and Immunodominant Cytotoxic T Lymphocyte Epitopes in Slow Progressors in HIV Type I Infection", AIDS Research and Human Retroviruses 12(18):1691-1698 (1996)
	✓	Hale et al, "T Cell Multideterminant Regions in the Human Immunodeficiency Virus Envelope: Toward Overcoming the Problem of Major Histocompatibility Complex Restriction", International Immunology 1(4):409-415 (1989)
	✓	Loktev et al, "Design of immunogens as components of a new generation of molecular vaccines", Journal of Biotechnology 44(1):129-137 (1996)

*Examiner

Date Considered

1/11/05

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)